BioSpace News Archive

Applied Research Works, Inc. announced Cozeva Bridge, a new service in Cozeva that consolidates medical information and incentives from health care provider groups and insurers into a unified view.

The College of American Pathologists welcomed the release of the House Ways and Means Committee’s Consumer Protections Against Surprise Medical Bills Act of 2020.

New biomarker data from the open-label extension (OLE) of the Phase 2 OASIS trial for etrasimod in patients with moderately to severely active ulcerative colitis (UC)

Supernus Pharmaceuticals, Inc. announced that the Company expects to report business results for the fourth quarter and full year of 2019 after 5:00 p.m. ET on Tuesday, February 25, 2020.

Preclinical models demonstrate robust remyelinating activity, functional myelin generation, and improved motor function

Da Volterra announced positive top-line results from a Phase 2 clinical trial ‘SHIELD’ evaluating DAV132 in patients receiving fluoroquinolone antibiotics.

BrainStorm Cell Therapeutics, Inc. announced that the Company recently held a high level meeting with the U.S. Food and Drug Administration to discuss potential NurOwn® regulatory pathways for approval in ALS.

TriLink BioTechnologies®, a Maravai LifeSciences company and a leader in the production of nucleic acids for research, diagnostics and therapeutics applications, announced the addition of two key executives to its leadership team.

ProMIS Neurosciences, Inc. announced its participation in Noble Capital Markets 16th Annual Investor Conference being held at the Hard Rock Hotel in Hollywood, Florida February 16-18, 2020.

BriaCell Therapeutics Corp. (“BriaCell” or the “Company”) (TSX-V:BCT) (OTCQB:BCTXD), a clinical-stage biotechnology company specializing in targeted immunotherapy for advanced breast cancer, today announced that Dr. Saveri Bhattacharya, a board-certified medical oncologist and recognized expert in breast cancer treatment at the Sidney Kimmel Cancer Center – Jefferson Health in Philadelphia, PA, has been selected to receive support from the Merck Investigator Studies Program (“MISP”).